Sensex falls more than 1 percent; metals, drugmakers drag

Image
Reuters MUMBAI
Last Updated : Mar 28 2016 | 3:07 PM IST

MUMBAI (Reuters) - India's stock markets fell more than 1 percent on Monday as investors booked profit in recent outperformers such as State Bank of India and Hindalco Industries ahead of a busy week of events, including the release of U.S. economic data and the expiry of domestic derivative contracts.

The broader NSE Nifty has risen 9.3 percent so far this month and is headed for its biggest monthly gain since October 2013 after the government stuck to its fiscal deficit target and on hopes of bigger-than-expected rate cuts by the central bank at its policy meeting April 5.

But caution prevailed on Monday as investors cautiously awaited U.S. economic data and speeches by Federal Reserve officials this week.

Meanwhile, monthly derivative contracts expire on Thursday, which also marks the end of the financial year.

Traders said they are still optimistic about markets in the long term, saying a pick-up in earnings would further add to the gains this month.

Any rally over the next few quarters will be earnings-driven as opposed to a macro play, said Varun Khandelwal, director at Delhi-based portfolio management firm Bullero Capital.

The broader NSE Nifty was trading lower by 1.37 percent at 2.54 p.m., while the benchmark BSE Sensex fell 1.46 percent. Recent outperformers were among the biggest losers: State Bank of India fell 4 percent after gaining 24 percent this month, while Hindalco dropped 8 percent after rising 32 percent.

Meanwhile, drug makers such as Sun Pharmaceuticals fell as investors switched to cement names Ambuja Cements and UltraTech Cement , traders said, adding these firms were expected to outperform the market because of the government's infrastructure push.

Natco Pharmaceuticals slumped 14 percent after the drug maker said it had received 483 observations from the U.S. Food and Drug Administration for its North India plant.

Meanwhile, IT stocks such as Infosys Technologies gained after Accenture Ltd raised its full-year revenue forecast.

(Reporting by Manoj Rawal; Editing by Subhranshu Sahu)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Mar 28 2016 | 2:55 PM IST

Next Story